Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...

First-line pembrolizumab “has consistent antitumor activity and safety” in patients with advanced urothelial carcinoma who are potentially ineligible for platinum‐based chemotherapy, researchers found ...

This study included a review of consecutive patients diagnosed with NMIBC between January 2005 and May 2023 to identify ...

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...

The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

TYRA-300 showed promising safety and preliminary antitumor activity in FGFR3-altered metastatic urothelial cancer, with a ...

Opens in a new tab or window The indication for sacituzumab govitecan (Trodelvy) in previously treated patients with locally advanced or metastatic urothelial cancer was withdrawn last month after ...

Application error: a client-side exception has occurred (see the browser console for more information).

Complete response (CR) observed in 86% (12/14) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who ...

Nectin-4 is a cell-adhesion molecule overexpressed in several tumor types, including breast, ovarian, lung, colorectal, pancreatic and urothelial cancer. Enfortumab vedotin (EV), an anti-Nectin-4 ...

Q3 2024 Earnings Call Transcript November 6, 2024 UroGen Pharma Ltd. beats earnings expectations. Reported EPS is $-0.55, ...